Takeda Earns US Nod for Oral EoE Drug after Resubmission

February 14, 2024
The US FDA on February 12 handed out the green light for Takeda Pharmaceutical’s Eohilia (budesonide oral suspension) after a resubmission, making it the first and only oral drug approved for the treatment of eosinophilic esophagitis (EoE) in the country...read more